<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Phil</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Ehret, Megan Jo</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Who Receives Guideline-Based Pharmacotherapy for Bipolar Depression?</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2009</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2009-07-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">27-28</style></pages><abstract><style  face="normal" font="default" size="100%">Several organizations have developed guidelines to assist with the treatment of patients with bipolar disorder (eg, The American Psychiatric Association, The Canadian Network for Mood and Anxiety Treatments, The Texas Medical Algorithm Project, and the National Institute for Health and Clinical Excellence); however, there is not much in the literature about how these guidelines are implemented in clinical practice.</style></abstract><number><style face="normal" font="default" size="100%">3</style></number><volume><style face="normal" font="default" size="100%">9</style></volume></record></records></xml>